VK2735 SC / Viking Therap - LARVOL DELTA

VANQUISH-2 SC VK2735 Study in Adults With Overweight and Type 2 Diabetes: Baseline Characteristics (OBESITY WEEK 2026) - No abstract available

Clinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Pipeline and Recent Corporate Highlights (PRNewswire) - "Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing...During the second quarter, both VANQUISH studies continued to proceed according to plan....VK2735 Maintenance Dosing Study Data Expected 3Q26...Exploratory endpoints will assess change in body weight from baseline, as well as change in body weight before and after transitioning to maintenance dosing."

P1 data • Trial status • Obesity • Type 2 Diabetes Mellitus

Viking also presented a second poster at ECO today highlighting the design and enrollment demographics of the ongoing Phase 3 VANQUISH-1 study of subcutaneous VK2735 in adults with obesity or who are overweight and have at least one weight-related comorbidity. (PRNewswire)

Trial status • Obesity

Treatment with Oral VK2735 Results in Significant Weight Loss: the Randomized, Placebo-Controlled, Dose-Finding VENTURE-2 Study (ECO 2026) - P2 | "Treatment discontinuation rates were 18% with placebo vs 20-38% with VK2735 and study discontinuation rates were 5% with placebo vs 8-13% with VK2735 in this dose-finding study. Preliminary findings with an oral tablet formulation of VK2735 show significant weight reduction in a short time span and a tolerability profile consistent with the clinical trial experience with activation of the incretin axis. Funding: Research relating to this abstract was funded by Viking Therapeutics, Inc Statistically significant differences in % change in body weight vs baseline and placebo were observed for all VK2735 doses >15 mg starting at Week 1 and continuing through 13 weeks. Fig."

Clinical • Constipation • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hypertension • Immunology • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Type 2 Diabetes Mellitus

VANQUISH-1: Phase 3 Trial With Enrollment of a Diverse Population to Test Efficacy of Subcutaneous VK2735 in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ECO 2026) - P2, P3 | "VANQUISH-1 enrolled individuals with overweight or obesity, representing a diverse population across a broad spectrum of age, gender, race/ethnicity, and comorbidities, which will reflect the target weight reduction patient populations in the US, EU, and UK."

Clinical • P3 data • Cardiovascular • Dyslipidemia • Genetic Disorders • Hepatology • Hypertension • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 (PRNewswire) - "At ECO, Viking will present a poster highlighting data from its Phase 2 VENTURE-Oral Dosing trial, focusing on key efficacy and safety endpoints, including weight loss and tolerability during the 13-week study. The second poster will highlight the design and enrollment demographics of the ongoing Phase 3 VANQUISH-1 study of subcutaneous VK2735 in adults with obesity or who are overweight and have at least one weight-related comorbidity."

P2 data • Trial status • Obesity

Pipeline and Recent Corporate Highlights (PRNewswire) - "Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled...Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26...VK2735 Maintenance Dosing Study Advances; Data Expected 3Q26....During the first quarter, the company filed an Investigational New Drug (IND) application for its lead amylin agonist VK3019. The company plans to initiate a Phase 1 trial evaluating VK3019 in 2Q26."

IND • New P1 trial • New P3 trial • P3 data • Obesity • Type 2 Diabetes Mellitus

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) (clinicaltrials.gov) - P3 | N=1100 | Active, not recruiting | Sponsor: Viking Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Concurrently, Viking is conducting the Phase 3 VANQUISH-1 study of subcutaneous VK2735 in patients who have obesity or are overweight. (PRNewswire) - "he company expects to report the results from this study in the third quarter of 2026."

P1 data • Obesity

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 (PRNewswire) - "The trial enrolled approximately 1,000 adults with type 2 diabetes and who have obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2). Enrolled patients have been randomized to one of four weekly treatment arms: VK2735 7.5 mg, 12.5 mg, 17.5 mg, and placebo...'As with the VANQUISH-1 study, we are happy to see a study of this size enroll quickly, which we believe speaks to the enthusiasm for new obesity treatments beyond those currently available. We look forward to completing the VANQUISH studies in 2027.'"

Enrollment closed • Trial completion date • Obesity • Type 2 Diabetes Mellitus

VK2735 Phase 1 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26. (PRNewswire) - "This trial is a randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2). All participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks."

Enrollment closed • P1 data • Obesity

...VANQUISH-1 over-enrolled ahead of schedule and VANQUISH-2 expected to complete enrollment in the first quarter of 2026. (PRNewswire)

Enrollment status • Obesity • Type 2 Diabetes Mellitus

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity (PRNewswire) - "The publication highlights the previously reported positive results from the Phase 2 VENTURE study of VK2735 in patients with obesity, which showed that the trial successfully achieved its primary and secondary endpoints. After 13 weekly subcutaneous doses, participants receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% with no signs of plateau....Treatment and study discontinuation rates among VK2735 cohorts were well-balanced compared with placebo."

P2 data • Obesity

In addition to the maintenance dosing study, Viking is currently conducting two Phase 3 studies evaluating subcutaneous VK2735 (VANQUISH-1 and VANQUISH-2). (PRNewswire) - "The VANQUISH-1 study has completed enrollment of approximately 4,650 adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study is enrolling approximately 1,100 adults with type 2 diabetes who have obesity or are overweight. Patients in both trials are being randomized to one of four weekly treatment arms: VK2735 7.5 mg; VK2735 12.5 mg; VK2735 17.5 mg; and placebo."

Enrollment closed • Trial status • Obesity • Type 2 Diabetes Mellitus

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity (PRNewswire) - "The trial enrolled approximately 180 adults with BMI ≥30 kg/m2 but who are otherwise healthy...All enrolled participants receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks. Following Week 19, participants are transitioned to a range of VK2735 maintenance dosing regimens including weekly, every other week, or monthly subcutaneous dosing, as well as daily oral dosing, weekly oral dosing, or placebo....'We look forward to reporting the results of this important study later this year.'"

Enrollment closed • P1 data • Obesity

Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. (PubMed, Obesity (Silver Spring)) - P2 | "All subcutaneous doses of VK2735 significantly reduced body weight. The AE profile of VK2735 was primarily gastrointestinal, with decreased reported frequency upon continued use."

Clinical • Journal • P2 data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

VANQUISH 1: VK2735 for Weight Management Phase 3 (clinicaltrials.gov) - P3 | N=4500 | Active, not recruiting | Sponsor: Viking Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 (PRNewswire) - "The trial enrolled approximately 4,650 adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition....Phase 3 VANQUISH-2 study of subcutaneous VK2735 in patients with type 2 diabetes who have obesity or are overweight...trial is currently enrolling patients, and the company expects to complete enrollment in the first quarter of 2026."

Enrollment status • Obesity

VANQUISH-1 Design: Phase 3 Trial of Subcutaneous VK2735 in Adults with Overweight or Obesity (OBESITY WEEK 2025) - P2 | "VANQUISH-1 will provide further data regarding the efficacy and safety of the dual GIP/GLP-1 receptor agonist scVK2735 for weight loss."

Clinical • P3 data • Diabetes • Dyslipidemia • Genetic Disorders • Hepatology • Hypertension • Immunology • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Osteoarthritis • Respiratory Diseases • Rheumatology • Sleep Disorder • Type 2 Diabetes Mellitus

Impact of Subcutaneous VK2735 on Weight, Prediabetes, and Cardiometabolic Status: The VENTURE Study (OBESITY WEEK 2025) - P2 | "In the VENTURE study, scVK2735 significantly reduced body weight and decreased the prevalence of prediabetes and MetS. Additional studies are in progress to explore the potential long-term health benefits with scVK2735."

Cardiovascular • Genetic Disorders • Metabolic Disorders • Obesity

Additional Poster Presentations Scheduled for American Heart Association Scientific Sessions 2025 (PRNewswire) - "One presentation will share the design of the company's ongoing Phase 3 VANQUISH-2 study of subcutaneous VK2735 in Type 2 diabetes patients with obesity or who are overweight."

Clinical protocol • Obesity

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2025 (PRNewswire) - "One ObesityWeek presentation will report results of an exploratory analysis from the company's Phase 2 VENTURE clinical trial, which evaluated 13 weeks of weekly treatment with a subcutaneous formulation of VK2735 in obese subjects....A second presentation will highlight the design of the company's ongoing Phase 3 VANQUISH-1 study of subcutaneous VK2735 in patients with obesity or who are overweight with at least one weight-related co-morbid condition."

Clinical protocol • P2 data • Obesity

VANQUISH 1: VK2735 for Weight Management Phase 3 (clinicaltrials.gov) - P3 | N=4500 | Recruiting | Sponsor: Viking Therapeutics, Inc.

New P3 trial • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) (clinicaltrials.gov) - P3 | N=1100 | Recruiting | Sponsor: Viking Therapeutics, Inc.

New P3 trial • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 (PRNewswire) - "Viking Therapeutics...announced the initiation of the VANQUISH Phase 3 clinical program for VK2735....The VANQUISH Phase 3 program includes two studies evaluating VK2735....Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks. The VANQUISH-1 study will target enrollment of approximately 4500 adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study will target enrollment of approximately 1100 adults with type 2 diabetes who are obese or overweight. Participants in both trials will be randomized to one of four weekly treatment arms: VK2735 7.5 mg, VK2735 12.5 mg, VK2735 17.5 mg, and placebo....'We...expect to report the results of the Phase 2 VENTURE-Oral Dosing study in the second half of this year'."

New P3 trial • P2 data • Obesity